Kathrin Thormann, Anne-Sophie Lüthi, Felix Deniau, Anja Heider, Simone Cazzaniga, Susanne Radonjic-Hoesli, Mathias Lehmann, Christoph Schlapbach, Elio L Herzog, Marco Kreuzer, Martin S Zinkernagel, Cezmi A Akdis, Denise C Zysset-Burri, Hans-Uwe Simon, Dagmar Simon
BACKGROUND: Dupilumab is used for the treatment of atopic dermatitis (AD). Approximately one third of AD patients develop a dupilumab-associated ocular surface disease (DAOSD), of which the pathomechanism is poorly understood. This study aimed at investigating inflammatory markers in tear fluids of patients on dupilumab therapy. METHODS: Tear fluids were collected from AD patients with DAOSD (ADwDAOSD), AD patients without DAOSD (ADw/oDAOSD), and non-AD patients before and during dupilumab therapy, and analyzed using a specialized proteomic approach quantifying inflammatory markers...
February 5, 2024: Allergy